Since raloxifene, a drug used in osteoporosis therapy, inhibits osteoclast, but not osteoblast functions, it has been suggested to improve recovery during implant surgery. The present paper describes an effective method to link raloxifene, through a covalent bond, to a nano-Hydroxyapatite-based biomaterial by interfacing with (3-aminopropyl)-Triethoxysilane as assessed by Infra Red-Fourier Transformed (IR-FT) spectroscopy and Scanning Electron Microscope (SEM). To evaluate the safety of this modified new material, the vitality of osteoblast-like cells cultured with the new biomaterial was then investigated. Raloxifene-conjugated HA-biomaterial has been shown to be a safe material easy to obtain which could be an interesting starting point for the use of a new functional biomaterial suitable in bone regeneration procedures.
BoccacciniARBlakerJJ. Bioactive composite materials for tissue engineering scaffolds. Expert Rev Med Devices2005; 2:303–17.
2.
HelenWMerryCLBlakerJJGoughJE. Three-dimensional culture of annulus fibrosus cells within PDLLA/Bioglass composite foam scaffolds: Assessment of cell attachment, proliferation and extracellular matrix production. Biomaterials2007; 28:2010–20.
3.
XuCWangYYuX. Evaluation of human mesenchymal stem cells response to biomimetic bioglass-collagen-hyaluronic acidphosphatidylserine composite scaffolds for bone tissue engineering. J Biomed Mater Res A2009; 88:264–73.
4.
BarbozaEPCaulaALFdeO Caula. Effect of recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge with space-providing biomaterials on the augmentation of chronic alveolar ridge defects. J Periodontol2004; 75:702–8.
5.
SigurdssonTJNygaardLTatakisDN. Periodontal repair in dogs: Evaluation of rhBMP–2 carriers. Int J Periodontics Restorative Dent1996; 16:524–37.
6.
TerheydenHJepsenSVogelerSTuckerMRuegerDC. Recombinant human osteogenic protein 1 in the rat mandibular augmentation model: Differences in morphology of the newly formed bone are dependent on the type of carrier. Mund Kiefer Gesichtschir1997; 1:272–5.
7.
GilleJDornBKekowJBrunsJBehrensP. Bone substitutes as carriers for transforming growth factor-beta(1) (TGF-beta(1)). Int Orthop2002; 26:203–6.
8.
BambiniFPellecchiaMMemeL. Antiinflammatory cytokines in peri-implant soft tissues: A preliminary study on humans using cDNA microarray technology. Eur J Inflamm2007; 5:121–7.
9.
BambiniFDe StefanoCAGiannottiLMemeLPellecchiaM. Influence of biphosphonates on the integration process of endosseous implants evaluated using single photon emission computerized tomography (SPECT). Minerva Stomatol2003; 52:331–8.
10.
GreinerSHWildemannBBackDA. Local application of zoledronic acid incorporated in a poly(D, L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop2008; 79:717–25.
11.
ShiXWangYRenLGongYWangDA. Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications. Pharm Res2009; 26:422–30.
12.
SrisubutSTeerakapongAVattraphodesTTaweechaisupapongS. Effect of local delivery of alendronate on bone formation in bioactive glass grafting in rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod2007; 104:e11–6.
13.
HoushmandBRahimiHGhanavatiFAlisadrAEslamiB. Boosting effect of bisphosphonates on osteoconductive materials: A histologic in vivo evaluation. J Periodontal Res2007; 42:119–23.
14.
LiuXMLeeHTReinhardtRAMarkyLAWangD. Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity. J Control Release2007; 122:54–62.
15.
GarbuzDSHuYKimWY. Enhanced gap filling and osteoconduction associated with alendronate-calcium phosphate-coated porous tantalum. J Bone Joint Surg Am2008; 90:1090–100.
16.
AholaMRichJKortesuoPKiesvaaraJSeppalaJYli-UrpoA. In vitro evaluation of biodegradable epsilon-caprolactone-co-D, L-lactide/silica xerogel composites containing toremifene citrate. Int J Pharm1999; 181:181–91.
17.
BambiniFGreciLMemeL. Raloxifene covalently bonded to titanium implants by interfacing with (3-aminopropyl)-triethoxysilane affects osteoblast-like cell gene expression. Int J Immunopathol Pharmacol2006; 19:905–14.
18.
RichelsonLSWahnerHWMeltonLJ3rdRiggsBL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med. 1984;311:1273–5.
19.
LindsayRHartDMAitkenJMMacDonaldEBAndersonJBClarkeAC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet. 1976; 1:1038–41.
20.
Lo MuzioLSantarelliAOrsiniGMemeLMattioli-BelmonteMDe FlorioIGattoRBambiniF. MG63 and MC3T3-E1 osteoblastic cell lines response to raloxifene. Eur J Inflamm2013; 11:797–804.
21.
BlackLJJonesCDFalconeJF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci1983; 32:1031–6.
22.
KumarVGreenSStackGBerryMJinJRChambonP. Functional domains of the human estrogen receptor. Cell1987; 51:941–51.
23.
SatoMMcClintockCKimJ. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats. J Bone Miner Res1994; 9:715–24.
24.
EvansGBryantHUMageeDSatoMTurnerRT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology1994; 134:2283–8.
25.
WebsterTJSiegelRWBiziosR. Osteoblast adhesion on nanophase ceramics. Biomaterials1999; 20:1221–7.
26.
LeporeSMililloLTrottaT. Adhesion and growth of osteoblast-like cells on laser-engineered porous titanium surface: Expression and localization of N-cadherin and β-catenin. J Biol Regul Homeost Agents2013; 27:531–41.
27.
WebsterTJErgunCDoremusRHSiegelRWBiziosR. Specific proteins mediate enhanced osteoblast adhesion on nanophase ceramics. J Biomed Mater Res2000; 51:475–83.
28.
WeiGMaPX. Structure and properties of nanohydroxyapatite/polymer composite scaffolds for bone tissue engineering. Biomaterials2004; 25:4749–57.
29.
SantarelliALo RussoLBambiniFCampisiGLo MuzioL. New perspectives in medical approach to therapy of head and neck squamous cell carcinoma. Minerva Stomatol2009; 58:445–52.
30.
Lo MuzioLSartiniDSantarelliA. Expression and prognostic significance of apoptotic genes in oral squamous cell carcinoma. Mol Carcinog2014; 53:264–71.
31.
BambiniFSantarelliAMarzoGRubiniCOrsiniGDi IorioDLo RussoLLo MuzioL. CD3 and CD20 expression in titanium vs zirconia peri-implant soft tissues: A human study. Eur J Inflamm2013; 11:305–10.
32.
WooKMSeoJZhangRMaPX. Suppression of apoptosis by enhanced protein adsorption on polymer/hydroxyapatite composite scaffolds. Biomaterials2007; 28:2622–30.
33.
ZhuWChenKLuW. In vitro study of nano-HA/PLLA composite scaffold for rabbit BMSC differentiation under TGF-β1 induction. In Vitro Cell Dev Biol Anim2014; 50:214–20.
TanRSheZWangMYuXJinHFengQ. Repair of rat calvarial bone defects by controlled release of rhBMP-2 from an injectable bone regeneration composite. J Tissue Eng Regen Med2012; 6:614–21.
36.
LiuHCLlEWangDSSuFWuXShiZPLvYWangJZ. Reconstruction of alveolar bone defects using bone morphogenetic protein 2 mediated rabbit dental pulp stem cells seeded on nanohydroxyapatite/collagen/poly(L-lactide). Tissue Eng Part A2011; 17:2417–33.
37.
WangXSongGLouT. Fabrication and characterization of nano-composite scaffold of PLLA/silane modified hydroxyapatite. Med Eng Phys2010; 32:391–97.
38.
DuprazAMde WijnJRv d MeerSAde GrootK. Characterization of silane-treated hydroxyapatite powders for use as filler in biodegradable composites. J Biomed Mater Res1996; 30:231–38.
39.
RavarianRWeiHDehghaniF. Improving the bioactivity of bioglass/(PMMA-co-MPM A) organic/inorganic hybrid. Conf Proc IEEE Eng Med Biol Soc2011;2011:3593–6.
